RATIONALE: Previous studies have demonstrated that several N-substituted 4', 4″-diF-benztropine (BZT) analogs with high dopamine transporter affinity selectively decreased cocaine self-administration without affecting food-maintained behavior in rats. OBJECTIVES: The present study examined if the decreases in cocaine self-administration are due to competition from excess behavioral activity (hyperlocomotion or stereotypy) induced by the BZT analogs alone or in combination with cocaine. RESULTS: Pretreatments with the typical dopamine uptake inhibitor methylphenidate [1.0, 3.2, and 10 mg/kg, intraperitoneally (i.p.)] dose-dependently shifted the cocaine self-administration dose-effect curve (0, 0.032, 0.1, 0.32, and 1.0 mg/kg/injection) leftward. The shift in the dose-effect curve was obtained at doses of methylphenidate that, when administered alone, also decreased food-maintained behavior and increased locomotor activity and stereotypy. In contrast, the N-substituted BZT analogs, JHW 007 (1.0, 3.2, and 10 mg/kg, i.p.), AHN 1-055 (10 mg/kg), and, AHN 2-005 (10 mg/kg), as previously reported, decreased the maximum for the cocaine self-administration dose-effect curve, and did so at doses that were virtually without effects on food-maintained behavior. Further, the BZT analogs alone had minimal effects on locomotor activity and stereotypies and did not appreciably change the effects of cocaine on these measures when administered in combination with cocaine. CONCLUSIONS: The present results suggest that the decrease in cocaine self-administration produced by the N-substituted BZT analogs is due to an antagonism of the reinforcing effects of cocaine rather than due to interference from competing behavioral overstimulation, and further supports the development of N-substituted BZT analogs as medications to treat cocaine abuse.
RATIONALE: Previous studies have demonstrated that several N-substituted 4', 4″-diF-benztropine (BZT) analogs with high dopamine transporter affinity selectively decreased cocaine self-administration without affecting food-maintained behavior in rats. OBJECTIVES: The present study examined if the decreases in cocaine self-administration are due to competition from excess behavioral activity (hyperlocomotion or stereotypy) induced by the BZT analogs alone or in combination with cocaine. RESULTS: Pretreatments with the typical dopamine uptake inhibitor methylphenidate [1.0, 3.2, and 10 mg/kg, intraperitoneally (i.p.)] dose-dependently shifted the cocaine self-administration dose-effect curve (0, 0.032, 0.1, 0.32, and 1.0 mg/kg/injection) leftward. The shift in the dose-effect curve was obtained at doses of methylphenidate that, when administered alone, also decreased food-maintained behavior and increased locomotor activity and stereotypy. In contrast, the N-substituted BZT analogs, JHW 007 (1.0, 3.2, and 10 mg/kg, i.p.), AHN 1-055 (10 mg/kg), and, AHN 2-005 (10 mg/kg), as previously reported, decreased the maximum for the cocaine self-administration dose-effect curve, and did so at doses that were virtually without effects on food-maintained behavior. Further, the BZT analogs alone had minimal effects on locomotor activity and stereotypies and did not appreciably change the effects of cocaine on these measures when administered in combination with cocaine. CONCLUSIONS: The present results suggest that the decrease in cocaine self-administration produced by the N-substituted BZT analogs is due to an antagonism of the reinforcing effects of cocaine rather than due to interference from competing behavioral overstimulation, and further supports the development of N-substituted BZT analogs as medications to treat cocaine abuse.
Authors: Clara Velázquez-Sánchez; Antonio Ferragud; Vicente Hernández-Rabaza; Amparo Nácher; Virginia Merino; Miguel Cardá; Juan Murga; Juan J Canales Journal: Neuropsychopharmacology Date: 2009-07-15 Impact factor: 7.853
Authors: Claus J Loland; Rajeev I Desai; Mu-Fa Zou; Jianjing Cao; Peter Grundt; Klaus Gerstbrein; Harald H Sitte; Amy Hauck Newman; Jonathan L Katz; Ulrik Gether Journal: Mol Pharmacol Date: 2007-10-31 Impact factor: 4.436
Authors: Gianluigi Tanda; Amy Hauck Newman; Aaron L Ebbs; Valeria Tronci; Jennifer L Green; Ronald J Tallarida; Jonathan L Katz Journal: J Pharmacol Exp Ther Date: 2009-05-29 Impact factor: 4.030
Authors: Weimin C Hong; Michael J Wasko; Derek S Wilkinson; Takato Hiranita; Libin Li; Shuichiro Hayashi; David B Snell; Jeffry D Madura; Christopher K Surratt; Jonathan L Katz Journal: J Pharmacol Exp Ther Date: 2018-06-26 Impact factor: 4.030
Authors: Dustin P Brown; Dennis T Rogers; Francois Pomerleau; Kirin B Siripurapu; Manish Kulshrestha; Greg A Gerhardt; John M Littleton Journal: Fitoterapia Date: 2016-04-20 Impact factor: 2.882
Authors: Takato Hiranita; Stephen J Kohut; Paul L Soto; Gianluigi Tanda; Theresa A Kopajtic; Jonathan L Katz Journal: J Pharmacol Exp Ther Date: 2013-11-05 Impact factor: 4.030
Authors: Jonathan L Katz; Takato Hiranita; Theresa A Kopajtic; Kenner C Rice; Christophe Mesangeau; Sanju Narayanan; Ahmed H Abdelazeem; Christopher R McCurdy Journal: J Pharmacol Exp Ther Date: 2016-04-21 Impact factor: 4.030
Authors: Takato Hiranita; Derek S Wilkinson; Weimin C Hong; Mu-Fa Zou; Theresa A Kopajtic; Paul L Soto; Carl R Lupica; Amy H Newman; Jonathan L Katz Journal: J Pharmacol Exp Ther Date: 2014-02-11 Impact factor: 4.030